Sindrom Guillain-Barre sebagai Gejala COVID-19 dan Potensi Efek Samping Pasca-Vaksinasi COVID-19

Joanesa Della Felista, Budi Riyanto Wreksoatmodjo

Abstract

COVID-19 adalah penyakit infeksi virus SARS-CoV-2. Gejala umum COVID-19 adalah pada saluran pernapasan, namun dapat ditemukan gejala neurologis antara lain sindrom Guillain-Barré (GBS). Hingga saat ini prevalensi kasus GBS pada pasien COVID-19 sekitar 0,15%. Selain itu, GBS
juga dapat merupakan salah satu efek samping setelah pemberian vaksin COVID-19. Insiden GBS lebih banyak pada penerima vaksin viral vector (0,38/100.000 dosis) dibandingkan penerima vaksin mRNA (0,18/100.000 dosis). Hingga saat ini belum ada laporan kasus GBS pasca-vaksinasi
berbasis protein. Hampir semua kasus GBS baik yang menerima vaksin berbasis mRNA maupun viral vector menunjukkan respons baik terhadap terapi IVIg.

 

COVID 19 is primarily a respiratory viral infection, but there are reports of neurological symptoms among patients; one of the accompanying neurological symptoms is Guillain-Barré Syndrome (GBS). Its prevalence among COVID 19 patients is approximately 0.15%. GBS is also reported
as a side effect after COVID vaccinations. Its incidence in greater among viral vector vaccine recipients (0.38/100.000 doses) as compared to mRNA vaccine recipients (0.18/ 100.000 doses). No GBS case was reported after protein-based vaccine administration. The majority of cases
responded well after IVIg therapy.

Full Text:

PDF

References

World Health Organization. Coronavirus [Internet]. [cited 2021 Nov 4]. Available from: https://www.who.int/health-topics/coronavirus

Our World in Data. Coronavirus pandemic (COVID-19) - the data [Internet]. [cited 2021 Nov 4]. Available from: https://ourworldindata.org/coronavirus-data?country=~IDN

Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: An overview of the reports. Neurol Sci. 2020;41(11):3149-56. doi: 10.1007/s10072-020-04693-y.

Ghannam M, Alshaer Q, Al-Chalabi M, Zakarna L, Robertson J, Manousakis G. Neurological involvement of coronavirus disease 2019: A systematic review. J Neurol. 2020;267(11):3135-53.

Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG, et al. Guillain-Barré syndrome following COVID-19: New infection, old complication? J Neurol. 2020;267(7):1877-9.

Trimboli M, Zoleo P, Arabia G, Gambardella A. Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine. Neurol Sci. 2021;42(11):4401-4402. doi: 10.1007/s10072-021-05523-5.

Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13(2):e13426.doi: 10.7759/cureus.13426.

Pedoman pencegahan dan pengendalian corona virus disease (COVID-19). Kementerian Kesehatan Republik Indonesia; 2020.

Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.

da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: Systematic review. Wiener Klinische Wochenschrift. 2021;133(7):377-82.

Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis—A review of current methods. Biosensors and Bioelectronics 2021;172:112752.

Lunn MP, Cornblath DR, Jacobs BC, Querol L, van Doorn PA, Hughes RA, et al. COVID-19 vaccine and Guillain-Barré syndrome: Let’s not leap to associations. Brain 2021;144(2):357-60.

Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barre syndrome. Lancet 2021;397(10280):1214–28.

Nguyen TP, Taylor RS, Boyle AGB. Guillain Barre syndrome (nursing). StatPearls Publishing; 2021.

Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clinics 2013;31(2):491-510.

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet 2016;388(10045):717-27.

Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: A review article. Neurol Sci. 2020;41:1667-71.

Yavarpour-Bali H, Ghasemi-Kasman M. Update on neurological manifestations of COVID-19. Life Sci. 2020;257:118063. doi: 10.1016/j.lfs.2020.118063.

Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020;77:8-12.

Palaiodimou L, Stefanou MI, Katsanos AH, Fragkou PC, Papadopoulou M, Moschovos C, et al. Prevalence, clinical characteristics and outcomes of Guillain− Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis. Eur J Neurol. 2021;28(10):3517–29.

Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID-19–associated Guillain-Barré syndrome: The early pandemic experience. Muscle & Nerve 2020;62(4):485-91.

Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574-6.

Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain–Barré syndrome spectrum associated with COVID-19: An up-to-date systematic review of 73 cases. J Neurol. 2021;268(4):1133-70.

Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep. 2021;14(6):e243629.

García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, Galnares-Olalde JA, Hernández-Vanegas LE, Figueroa-Cucurachi M, et al. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol. 2021;230:108-18.

Bonifacio GB, Patel D, Cook S, Purcaru E, Couzins M, Domjan J, et al. Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine. J Neurol Neurosurg Psychiatr. 2022 Mar;93(3):341-342. doi: 10.1136/jnnp-2021-327027.

Zito A, Alfonsi E, Franciotta D, Todisco M, Gastaldi M, Ramusino MC, et al. COVID-19 and Guillain–Barré syndrome: A case report and review of literature. Frontiers in Neurology 2020;11:909.

Oguz-Akarsu E, Ozpar R, Mirzayev H, Acet-Ozturk NA, Hakyemez B, Ediger D, et al. Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle & Nerve 2020;62(3):54-7.

Gittermann LT, Feris SV, von Oetinger Giacoman A. Relation between COVID-19 and Guillain-Barré syndrome in adults: A systematic review. Neurología (English Edition) 2020;35:646—54.

Sriwastava S, Kataria S, Tandon M, Patel J, Patel R, Jowkar A, et al. Guillain Barré syndrome and its variants as a manifestation of COVID-19: A systemic review of case report and case series. J Neurol Sci. 2021;420:117263. doi: 10.1016/j.jns.2020.117263.

Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111–6.

Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology 2021;10(8):752.

Scendoni R, Petrelli C, Scaloni G, Logullo FO. Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine. Human Vaccines & Immunotherapeutics. 2021;17(11):4093-6. doi:10.1080/21645515.2021.1954826.

Dyer O. Covid-19: Regulators warn that rare Guillain-Barré cases may link to J&J and AstraZeneca vaccines. BMJ. 2021;374:1786.

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.

Lemaire D, Barbosa T, Rihet P. Coping with genetic diversity: The contribution of pathogen and human genomics to modern vaccinology. Brazilian J Med Biol Res. 2012;45:376-85.

McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Reports CP. 2021;14(7):244125.

Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Internat J Infect Dis. 2021;111:219-26.

Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384(20):1899-909.

Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature Med. 2021;27(12):2144-53. doi: 10.1038/s41591-021-01556-7.

d’Orsi G, Sica S, Maiorano A, Melchionda D, Lalla A, Montemurro L, et al. Guillain-Barré syndrome as only manifestation of COVID-19 infection. Clin Neurol Neurosurg. 2021;207:106775.

Refbacks

  • There are currently no refbacks.